Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2016-08-27T04:08:42Z | - |
dc.date.available | 2016-08-27T04:08:42Z | - |
dc.date.issued | 2015 | * |
dc.identifier.issn | 1949-2553 | * |
dc.identifier.other | OAK-16231 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/217938 | - |
dc.description.abstract | This prospective observational study evaluated the efficacy and safety of long-term decitabine treatment in patients with myelodysplastic syndrome (MDS). Decitabine 20 mg/m(2)/day was administered intravenously for 5 consecutive days every 4 weeks to MDS patients in intermediate-1 or higher International Prognostic Scoring System (IPSS) risk categories. Active antimicrobial prophylaxis was given to prevent infectious complications. Overall response rate (ORR), overall survival (OS), progression-free survival (PFS), and time to response were evaluated, as were adverse events. The final analysis included 132 patients. IPSS risk was intermediate-2/high in 34.9% patients. The patients received a median of 5 cycles, with responders receiving a median of 8 cycles (range, 2-30). ORR was 62.9% (complete response [CR], 36; partial response [PR], 3; marrow complete response [mCR], 19; and hematologic improvement, 25). Among responders, 39% showed first response at cycle 3 or later. OS at 2 years was 60.9%, with 17% progressing to acute myeloid leukemia. PFS at 2 years was 51.0%. Patients achieving mCR showed comparable survival outcomes to those with CR/PR. With active antibiotic prophylaxis, febrile neutropenia events occurred in 61 of 1,033 (6%) cycles. Long-term decitabine treatment with antibiotic prophylaxis showed favorable outcomes in MDS patients, and mCR predicted favorable survival outcomes. | * |
dc.language | English | * |
dc.publisher | IMPACT JOURNALS LLC | * |
dc.subject | decitabine | * |
dc.subject | long-term treatment | * |
dc.subject | myelodysplastic syndrome | * |
dc.title | A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome | * |
dc.type | Article | * |
dc.relation.issue | 42 | * |
dc.relation.volume | 6 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 44985 | * |
dc.relation.lastpage | 44994 | * |
dc.relation.journaltitle | ONCOTARGET | * |
dc.identifier.wosid | WOS:000369908800068 | * |
dc.identifier.scopusid | 2-s2.0-84953373584 | * |
dc.author.google | Jeong, Seong Hyun | * |
dc.author.google | Kim, Yoo-Jin | * |
dc.author.google | Lee, Je-Hwan | * |
dc.author.google | Kim, Yeo-Kyeoung | * |
dc.author.google | Kim, Soo Jeong | * |
dc.author.google | Park, Sung Kyu | * |
dc.author.google | Do, Young Rok | * |
dc.author.google | Kim, Inho | * |
dc.author.google | Mun, Yeung-Chul | * |
dc.author.google | Kim, Hoon Gu | * |
dc.author.google | Lee, Won Sik | * |
dc.author.google | Yi, Hyeon Gyu | * |
dc.author.google | Joo, Young-Don | * |
dc.author.google | Choi, Chul Won | * |
dc.author.google | Kim, Suk Ran | * |
dc.author.google | Na, Sang Min | * |
dc.author.google | Jang, Jun Ho | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240123100838 | * |